What Rexaler Treats: Main Uses and Benefits

Rexaler is commonly used across conditions presenting with episodic or fluctuating symptom patterns, primarily focused on providing symptomatic support in the domain of allergic disease. Its applications include the relief of symptoms associated with both seasonal and perennial allergic rhinitis and the uncomplicated skin manifestations of chronic idiopathic urticaria (CIU), or hives.

Rexaler helps address symptom clusters that may become intense or disruptive, such as sneezing, runny nose (rhinorrhea), nasal and skin itching (pruritus), and watery eyes. Used in clinical settings that involve acute or unstable symptom patterns, the medication is applied during phases when symptoms become temporarily overwhelming. It provides supportive relief when symptoms interfere with routine activities. The medication may assist with maintaining comfort by easing the overall symptom burden, and is relevant when short-term symptomatic assistance is needed to improve day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Allergic Symptoms

Who can and cannot use Rexaler?

The eligibility to use Rexaler (Levocetirizine) is strictly defined by official regulatory labeling, focusing on specific health conditions and age groups.

Contraindicated Populations

Use of this medicine is absolutely prohibited (contraindicated) for individuals with a known hypersensitivity to levocetirizine, cetirizine, or any piperazine derivatives. It is also contraindicated in patients with end-stage renal disease, defined as a creatinine clearance ( CLcr) less than 10 mL/min, including those on hemodialysis. A specific pediatric restriction prohibits use in children aged 6 months to 11 years who have any degree of impaired kidney function.

Age and Conditional Use

The safety and efficacy of Rexaler are not established for infants under six months of age. For adolescents and adults with mild, moderate, or severe renal impairment, use is permissible but requires careful adjustment. Additionally, regulatory documents advise that the medicine be used with caution in patients who have predisposing factors for urinary retention, such as prostatic hyperplasia.

Pregnancy and Lactation Status

Rexaler's eligibility during pregnancy is formally classified as FDA Category B. However, use during lactation is generally not recommended because the medication is expected to be excreted in human milk.

Interactions with other medicines and products

Co-administration of Levocetirizine dihydrochloride with alcohol or other Central Nervous System (CNS) depressants should be officially avoided. This restriction is based on the potential for an additive pharmacodynamic effect, resulting in additional reductions in alertness and impairment of CNS performance. The regulatory label provides no mandatory timing separation rules for any co-administered substance.

Regarding exposure-modifying effects, studies involving the racemic mixture (Cetirizine) show that Ritonavir co-administration increases Cetirizine exposure (AUC) by approximately 42% and reduces Ritonavir clearance by 20%. Co-administration with Theophylline was also documented to decrease Cetirizine clearance by 16%.

The medicine is documented as being unlikely to produce metabolic interactions with other products. In vitro data confirm that Levocetirizine does not act as an inhibitor or inducer of major liver CYP isoenzymes (1A2, 2C9, 3A4, etc.).

Taking the medicine with food is officially documented to slow the rate of absorption, resulting in a delay in Tmax and a decrease in Cmax, but this does not alter the total extent of drug exposure ( AUC).

Population-specific notes highlight that interaction risk is linked to renal function. Total body clearance was documented as 33% lower in geriatric patients (65–74 years), demonstrating how the dependence on kidney function can lead to potentially greater exposure in populations with impaired renal status.

Rexaler is a centrally acting compound that exerts its primary pharmacodynamic effect within the brain stem, specifically targeting descending noradrenergic and serotonergic pathways. The molecule functions as an antagonist at multiple receptor subtypes, including serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, and alpha1-adrenergic receptors. It also exhibits antagonistic properties at muscarinic acetylcholine M1, M2, and M3 receptors, and histamine H1 receptors. This multi-receptor antagonism modulates the synaptic balance of excitation and inhibition on alpha and gamma motor systems. The resulting downstream cascade is a decline in tonic somatic motor activity. The net system-level physiological consequence is a reduction in the hyperactivity of skeletal muscle within the central nervous system, without direct effect on the neuromuscular junction or peripheral muscle fiber contractility.

How Rexaler Is Used

The usage of Rexaler (Levocetirizine dihydrochloride) follows specific administration parameters, establishing defined routes, dose ranges, and adjustments based on physiological status. The medication is classified for oral administration only and is prescribed for a once daily dose, typically administered in the evening. This scheduling ensures a consistent concentration over a 24-hour period. Administration is flexible and permitted with or without food.

General Dosing Regimens by Age

The standard dose for adults and children 12 years of age and older is 5 mg once daily. A reduced dose of 2.5 mg once daily may be appropriate for some patients. The maximum allowable daily intake is strictly limited to 5 mg per day. For children 6 to 11 years of age, the recommended dose is 2.5 mg once daily. For the youngest approved group, children 6 months to 5 years of age, the dose is 1.25 mg once daily, using the oral solution. The oral solution requires an accurate measuring device for proper use.

Dose Adjustment in Impaired Renal Function

Because the active ingredient is primarily excreted by the kidneys, dose modification is mandated for patients 12 years of age and older who have decreased renal function, as determined by creatinine clearance (CLcr). No specific dose adjustment is needed for individuals with solely hepatic impairment. In the event a dose is missed, the protocol is to skip the missed dose if the next dose is due shortly, and not to double the dose.

Research evidence / Overview of Studies for Rexaler (Levocetirizine)

This section provides an overview of the key clinical research that was studied for levocetirizine, focusing on the study designs, the types of outcomes monitored, and where scientific evidence remains limited, without offering any clinical advice.

Evidence for use in Seasonal Allergic Rhinitis (SAR)

Research exploring how symptoms change over time in seasonal allergic rhinitis is primarily based on short-term, placebo-controlled randomized clinical trials (RCTs) and systematic reviews. These studies typically include adults and children who experience episodic or acute symptom patterns related to seasonal allergens. The research examined patient-reported outcomes, monitoring changes in Total Symptom Scores (TSS), which combine measures of physical discomfort. The research reported distinct numerical patterns in symptom score measurements between the levocetirizine group and the placebo group in the studies. Results apply only to the short-term intervals studied, typically spanning two to four weeks, meaning there is limited information regarding the persistence of observed patterns over an entire allergy season.

Evidence for use in Chronic Idiopathic Urticaria (CIU)

Evidence for chronic idiopathic urticaria (hives of unknown cause) comes mainly from short-term randomized controlled trials conducted in adults and children with recurrent symptoms. The study outcomes examined were linked to patient-reported discomfort. Researchers monitored measures related to the severity of pruritus (itching) and the size and number of wheals (hives). Findings indicate that patients in the levocetirizine groups showed distinct measured changes in reported itching and wheal visibility during the study period. A key limitation is that definitive RCTs typically have follow-up durations that were limited, offering insufficient long-term data for patients who may require management over many months or years.

What is Still Uncertain About Rexaler's Research

The current body of research highlights areas where further investigation is needed. Specifically, there is limited information for long-term outcomes on the durability of the observed symptom patterns for use extending beyond six months for chronic conditions like perennial allergic rhinitis. Evidence is also less characterized for urticaria that is non-idiopathic (where a cause is known). Research provides context but not individual predictions; findings describe group patterns, and research does not determine whether an individual will respond similarly.

Common questions about Rexaler (FAQ)

Q: How quickly can I expect Rexaler to start working?

Studies indicate that the drug’s onset of action is generally observed within one hour after administration. This means the medicine is designed to start its therapeutic action relatively quickly upon taking it.

Q: Can Rexaler cause difficulties with driving or operating machinery?

Official regulatory information states that activities requiring mental alertness, such as driving or operating hazardous machinery, should be avoided until an individual knows how the medicine affects them. This warning is in place due to the potential for the medicine to cause drowsiness or reduced alertness.

Q: What is the half-life of Rexaler?

The half-life is a scientific measurement indicating how long it takes for half the concentration of the drug to be eliminated from the bloodstream. Regulatory documents state that the mean plasma half-life of the active ingredient in adult healthy subjects is approximately 8 to 9 hours.

Q: How long does Rexaler stay in my system after the last dose?

The length of time the active ingredient remains in the system is determined by its half-life. The mean plasma half-life in healthy adults is documented in regulatory sources to be approximately 8 to 9 hours, which guides its once-daily dosing schedule.

Q: I've heard about a 'black box warning'—does Rexaler have one?

The official regulatory product information confirms that Levocetirizine dihydrochloride does not carry a U.S. Food and Drug Administration (FDA) mandated Boxed Warning. This specific type of warning is typically reserved for serious safety concerns in certain medications.

Q: Is Rexaler a controlled substance?

The active ingredient in Rexaler, Levocetirizine dihydrochloride, is a widely used antihistamine. Official regulatory bodies, including the U.S. Drug Enforcement Administration (DEA) and the FDA, do not classify this compound as a controlled substance.

Q: Is there a generic version of Rexaler available?

The active ingredient, Levocetirizine dihydrochloride, is available in the marketplace in various forms. According to official product listings, it is available under the brand name as well as in authorized generic and store-brand formulations.

Q: Does Rexaler cause weight gain or weight loss?

Regulatory documents list weight gain and increased appetite as adverse reactions that were reported with less common frequency in clinical trial experience for some age groups.

Q: Does Rexaler affect sleep or cause insomnia?

According to official regulatory documents, somnolence, which is the term for sleepiness or drowsiness, is listed as a common adverse reaction reported in clinical trials.

Q: Can I take Rexaler with my morning coffee?

The official product information states that Rexaler can be taken either with or without food. The medicine's regulatory label does not contain specific information or warnings about co-administering it with non-food beverages like coffee or caffeine.

Q: Can Rexaler interact with cold and flu remedies?

Regulatory documents caution against using Rexaler alongside alcohol or other Central Nervous System (CNS) depressants because of the potential for an additive effect that reduces alertness. Since many over-the-counter cold and flu remedies may contain CNS depressant components, this general caution applies.

Q: Can Rexaler interact with common over-the-counter painkillers?

Drug interaction resources indicate that the medicine has generally been studied alongside single-ingredient acetaminophen (paracetamol) without major reported interactions. However, caution is advised when taking Rexaler with any products that contain CNS depressant components.

Q: Is Rexaler safe for older adults?

Official documents state that caution is advised when the medicine is used in older adults (65 years and older). This is because the regulatory information notes a potential increased risk of specific side effects, such as urinary retention, related to the decline in kidney function often seen in this age group.

Q: Does Rexaler affect blood pressure or heart rate?

Official documents note that low blood pressure has been documented as a serious adverse reaction reported during post-marketing surveillance. This event may be associated with severe hypersensitivity reactions.

Q: Is it okay to crush or chew Rexaler tablets?

The Rexaler tablet is designed as a film-coated formulation intended for swallowing whole. The regulatory information addresses swallowing difficulty by discussing the availability and use of the oral solution (liquid form) for patients who cannot swallow tablets.

Q: What is the average duration of treatment with Rexaler?

The medicine is indicated for managing conditions classified as seasonal or perennial (chronic) allergies and hives. This means the duration of use is highly variable and depends entirely on the type and persistence of the underlying condition being addressed.

Q: What happens if I take Rexaler for a long time?

Clinical research has provided limited information on the outcomes for patients using the medicine for intervals extending beyond six months. Official safety documents also note that severe itching (pruritus) has been reported as a rare adverse event following the discontinuation of the medicine after long-term daily use.

Q: If I stop taking Rexaler, will I have withdrawal symptoms?

Official safety documents note that severe itching (pruritus) has been reported as a rare event in post-marketing surveillance, specifically developing after the medicine was stopped following long-term administration.

Q: How often are the side effects of Rexaler reported in studies?

Side effects are categorized in official regulatory documents based on how frequently they occurred in clinical studies and after marketing. They are generally grouped into Common (frequently reported in trials), Uncommon (reported at lower incidence rates), and events reported Post-marketing (documented after the medicine became available).

Q: Can Rexaler affect fertility or reproductive health?

The regulatory label contains information based on the results of animal reproductive toxicology studies. These studies are typically conducted to examine the potential effects of the medicine on general fertility and reproductive health.

Official Storage Conditions

Rexaler (Levocetirizine Dihydrochloride) must be stored at a Controlled Room Temperature, officially defined as 20 C to 25 C (68 F to 77 F), with allowed temperature excursions up to 30 C (86 F). The medicine must be kept from freezing and stored away from heat, moisture, and direct light.

Packaging and Safety

Store the product in its tightly closed container and do not use it after the printed expiry date. It is a mandatory requirement to keep this medicine out of the sight and reach of children to prevent accidental exposure.

Disposal Instructions

Unused or expired product must not be thrown away via wastewater or household waste (trash). Regulatory guidance instructs individuals to ask a pharmacist how to properly discard the medicine to ensure compliance with local and national pharmaceutical waste handling procedures.